Lv52
1130 积分 2025-04-02 加入
P1189: INITIAL SAFETY RUN-IN RESULTS OF THE PHASE III POLARGO TRIAL: POLATUZUMAB VEDOTIN PLUS RITUXIMAB, GEMCITABINE, AND OXALIPLATIN IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
1个月前
已完结
POLARGO: Randomized Phase III Study of Polatuzumab Vedotin Plus Rituximab, Gemcitabine, and Oxaliplatin in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
1个月前
已完结
R-GemOx Plus Nivolumab Vs R-GemOx As Second-Line Therapy for Large B-Cell Lymphoma in Transplant-Ineligible Patients: Interim Analysis of the Niveau Trial, an International, Randomized Phase 3 Study of the AGMT, GLA, HOVON, Lysa and PLRG
1个月前
已完结
Preliminary results of a phase II study of rituximab (R), gemcitabine (Gem), oxaliplatin (Ox) plus enzastaurin (ENZ) followed by ENZ maintenance as salvage regimen for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)
1个月前
已关闭
ABCL-006 Azacytidine plus rituximab–gemcitabine–oxaliplatin as salvage treatment in patients with relapsed/refractory diffuse large B-cell lymphoma
1个月前
已完结
Outcomes of Relapsed or Refractory Diffuse Large B‐Cell Lymphoma Treated With R‐GemOx: A Multicenter Cohort Study
1个月前
已完结
Efficacy and safety of polatuzumab-vedotin plus bendamustine and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma: A systematic review and meta-analysis
1个月前
已关闭
Myeloid sarcoma of the breast as a first manifestation of acute myeloid leukemia: A case report
4个月前
已关闭
ABCL-006 Azacytidine plus rituximab–gemcitabine–oxaliplatin as salvage treatment in patients with relapsed/refractory diffuse large B-cell lymphoma
4个月前
已完结
Preliminary results of a phase II study of rituximab (R), gemcitabine (Gem), oxaliplatin (Ox) plus enzastaurin (ENZ) followed by ENZ maintenance as salvage regimen for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)
4个月前
已关闭
皖公网安备34019202002308
